Physician

Anthony Rooklin, MD

According to 2025 Medicare claims, Anthony Rooklin, MD (NPI: 1013008333) practices allergy/immunology in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Delaware, PA. This provider's primary affiliated billing organization is ASTHMA AND ALLERGY ASSOCIATES PC (NPI: 1891860250; TIN: 232501647) and primary practice location at 19342-1079.

Rooklin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 390 traditional Medicare patients, billed 38,469 HCPCS/CPT codes, and received $1,299,529 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,853 prescription claims across 334 beneficiaries totaling $1,421,605 in drug costs, led by Xolair (Omalizumab). DME data shows 166 claims. Open Payments data shows 161 records totaling $51,506. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $85,587 to $1,299,529. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,865,673 to $1,421,605. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $7,982 and ending at $5,588.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	275	3,390	$85,587
2016	291	2,255	$62,796
2017	340	3,532	$77,872
2018	386	4,552	$111,673
2019	378	8,529	$283,243
2020	377	13,439	$495,265
2021	401	24,689	$871,018
2022	360	30,737	$1,064,676
2023	375	40,260	$1,386,140
2024	390	38,469	$1,299,529

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	183	1,137	$1,865,673
2016	217	1,348	$1,178,144
2017	260	1,559	$1,020,098
2018	277	1,621	$664,139
2019	281	1,522	$551,537
2020	282	1,749	$659,171
2021	325	1,956	$774,093
2022	308	1,822	$792,109
2023	333	1,894	$1,872,613
2024	334	1,853	$1,421,605

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	95	$100,542
2016	N/R	133	$45,016
2017	N/R	124	$100,780
2018	N/R	284	$204,534
2019	N/R	277	$137,892
2020	N/R	336	$273,474
2021	14	307	$253,141
2022	N/R	168	$252,011
2023	N/R	216	$266,012
2024	14	166	$124,079

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	67	67	$122
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	209	342	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	81	107	$64
94010	Test to measure expiratory airflow and volume	111	156	$22
95117	Professional service for multiple injections of allergen	76	682	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xolair	Omalizumab	34	1,575	$203,983
Hyqvia	Igg/Hyaluronidase,recombinant	18	504	$141,924
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	52	2,880	$56,308
Dupixent Pen	Dupilumab	13	364	$48,646
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	61	2,160	$44,804

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	17	$38,402
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	12	$37,780
J1551	Injection, immune globulin (cutaquig), 100 mg	N	N/R	11	$36,648
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	23	$7,582
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	19	$1,249

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	161	$51,506	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anthony Rooklin, MD?

Tedicare shows public-source Medicare data for Anthony Rooklin, MD (NPI 1013008333), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anthony Rooklin, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Anthony Rooklin, MD?

Anthony Rooklin, MD is linked to ASTHMA AND ALLERGY ASSOCIATES PC (billing NPI 1891860250) in the available physician profile data.

Does Anthony Rooklin, MD have Open Payments data?

Anthony Rooklin, MD has 161 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.